Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: A future dilemma for micro-oncology

Future Oncology

Volumn 9, Issue 4, 2013, Pages 505-525

  Darwiche, Kaid ^a   Zarogoulidis, Paul ^a,b   Karamanos, Nikos K ^c   Domvri, Kalliopi ^b   Chatzaki, Ekaterini ^d   Constantinidis, Theodoros C ^d   Kakolyris, Stylianos ^e   Zarogoulidis, Konstantinos ^b  

^a RUHRLANDKLINIK   (Germany)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^e UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

Author keywords

aerosol chemotherapy; micro oncology; non small cell lung cancer; NSCLC; occupational safety

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOSPORIN A; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; PLATINUM DERIVATIVE; PROSTAGLANDIN E1; RUBITECAN;

ACUTE LUNG INJURY; AEROSOL; AGEUSIA; ALLERGIC PNEUMONITIS; ANOSMIA; BREATHING PATTERN; BRONCHITIS; BRONCHOSPASM; CANCER CHEMOTHERAPY; CARDIOTOXICITY; COUGHING; DRUG ABSORPTION; DRUG ADSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; ENVIRONMENTAL STRESS; EUKARYOTIC FLAGELLUM; FATIGUE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERTENSION; HYPOXIA; INHALATION; LOWER RESPIRATORY TRACT; LUNG ALVEOLUS MACROPHAGE; LUNG EDEMA; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MACROPHAGE FUNCTION; MICROMETASTASIS; NAUSEA; NEBULIZER; NONHUMAN; NOSE OBSTRUCTION; OXIDATIVE STRESS; PARTICULATE MATTER; PH; PHARYNGITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN IRRITATION; THORAX PAIN; TUMOR MICROENVIRONMENT; WHEEZING;

ADMINISTRATION, INHALATION; ADSORPTION; AEROSOLS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DOXORUBICIN; FLUOROURACIL; HUMANS; LUNG; LUNG NEOPLASMS; PARTICLE SIZE; PLATINUM COMPOUNDS; SMALL CELL LUNG CARCINOMA; TAXOIDS;

EID: 84875938015     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.205     Document Type: Review

References (117)

1. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J. Thorac. Oncol. 6(8), 1379-1391 (2011).
2. Giacomini KM, Yee SW, Ratain MJ, Weinshilboum RM, Kamatani N, Nakamura Y. Pharmacogenomics and patient care: one size does not fit all. Sci. Transl. Med. 4(153), 153ps118 (2012).
3. Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J. Thorac. Oncol. 7(10), 1583-1593 (2012).
4. Nakata A, Gotoh N. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin. Ther. Targets 16(8), 771-781 (2012).
5. Zarogoulidis K, Mylonaki E, Kakavelas P, et al. Topotecan-carboplatin- etoposide combination as 1st line treatment in patients with small cell lung cancer. Lung Cancer 66(2), 226-230 (2009).
6. Zarogoulidis K, Kontakiotis T, Hatziapostolou P, et al. A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer 32(3), 281-287 (2001). (Pubitemid 32487688)
7. Tentes AA, Korakianitis OS, Kakolyris S, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer. Tumori 96(3), 411-416 (2010).
8. Porpodis K, Karanikas M, Zarogoulidis P, et al. A case of typical pulmonary carcinoid tumor treated with bronchoscopic therapy followed by lobectomy. J. Multidiscip. Healthc. 5, 47-51 (2012).
9. Zarogoulidis P, Chatzaki E, Hohenforst- Schmidt W, et al. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review. Cancer Gene. Ther. 19(9), 593-600 (2012).
10. Celikoglu F, Celikoglu SI, Goldberg EP. Bronchoscopic intratumoral chemotherapy of lung cancer. Lung Cancer 61(1), 1-12 (2008).
11. Tatsumura T, Yamamoto K, Murakami A, Tsuda M, Sugiyama S. New chemotherapeutic method for the treatment of tracheal and bronchial cancers - nebulization chemotherapy. Gan. No Rinsho. 29(7), 765-770 (1983).
12. Zarogoulidis P, Eleftheriadou E, Sapardanis I, et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest. N. Drugs 30(4), 1628-1640 (2012).
13. Zarogoulidis P, Chatzaki E, Porpodis K, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int. J. Nanomed. 7, 1551-1572 (2012).
14. Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br. J. Cancer 68(6), 1146-1149 (1993). (Pubitemid 23356667)
15. Hershey AE, Kurzman ID, Forrest LJ, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin. Cancer Res. 5(9), 2653-2659 (1999). (Pubitemid 29437354)
16. Gagnadoux F, Hureaux J, Vecellio L, et al. Aerosolized chemotherapy. J. Aerosol Med. Pulm. Drug Deliv. 21(1), 61-70 (2008).
17. Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus PE. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J. Aerosol Med. 19(3), 385-391 (2006). (Pubitemid 44735394)
18. Selting K, Waldrep JC, Reinero C, et al. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J. Aerosol Med. Pulm. Drug Deliv. 21(3), 255-268 (2008).
19. Khanna C, Vail DM. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr. Cancer Drug Targets 3(4), 265-273 (2003). (Pubitemid 36944260)
20. Otterson GA, Villalona-Calero MA, Hicks W, et al. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin. Cancer Res. 16(8), 2466-2473 (2010).
21. Roa WH, Azarmi S, Al-Hallak MH, Finlay WH, Magliocco AM, Lobenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J. Control. Release 150(1), 49-55 (2011).
22. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin. Cancer Res. 7(10), 3258-3262 (2001). (Pubitemid 32963851)
23. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc. Natl Acad. Sci. USA 107(23), 10737-10742 (2010).
24. Otterson GA, Villalona-Calero MA, Sharma S, et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin. Cancer Res. 13(4), 1246-1252 (2007). (Pubitemid 46424066)
25. Wittgen BP, Kunst PW, Van Der Born K, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res. 13(8), 2414-2421 (2007). (Pubitemid 46698592)
26. Knight V, Koshkina NV, Golunski E, Roberts LE, Gilbert BE. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. Trans. Am. Clin. Climatol. Assoc. 115, 395-404; discussion 404 (2004).
27. Wattenberg LW, Wiedmann TS, Estensen RD. Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Cancer Res. 64(7), 2347-2349 (2004). (Pubitemid 38523886)
28. Hureaux J, Lagarce F, Gagnadoux F, et al. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur. J. Pharm. Biopharm. 73(2), 239-246 (2009).
29. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of biotinylated-EGF- modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 30(20), 3476-3485 (2009).
30. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)- camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res. 10(7), 2319-2326 (2004). (Pubitemid 38445689)
31. Lawson KA, Anderson K, Snyder RM, et al. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother. Pharmacol. 54(5), 421-431 (2004). (Pubitemid 39462967)
32. Hitzman CJ, Wattenberg LW, Wiedmann TS. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J. Pharm. Sci. 95(6), 1196-1211 (2006). (Pubitemid 43874436)
33. Rodriguez CO Jr, Crabbs TA, Wilson DW, et al. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J. Aerosol Med. Pulm. Drug Deliv. 23(4), 197-206 (2010).
34. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int. J. Cancer 116(3), 458-463 (2005). (Pubitemid 40993344)
35. Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother. Pharmacol. 44(3), 187-192 (1999). (Pubitemid 29350173)
36. Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. J. Clin. Oncol. 19(6), 1839-1847 (2001). (Pubitemid 32230887)
37. Koshkina NV, Knight V, Gilbert BE, Golunski E, Roberts L, Waldrep JC. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2- enriched air: pharmacokinetic studies. Cancer Chemother. Pharmacol. 47(5), 451-456 (2001). (Pubitemid 32397623)
38. Hitzman CJ, Elmquist WF, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: in vitro and in vivo optimization of lipid coated nanoparticles. J. Pharm. Sci. 95(5), 1127-1143 (2006). (Pubitemid 43723170)
39. Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J. Pharm. Sci. 95(5), 1114-1126 (2006). (Pubitemid 43723169)
40. Lawson KA, Anderson K, Menchaca M, et al. Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol. Cancer Ther. 2(5), 437-444 (2003).
41. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharmacol. 44(3), 177-186 (1999). (Pubitemid 29350172)
42. Gagnadoux F, Leblond V, Vecellio L, et al. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother. Pharmacol. 58(2), 237-244 (2006).
43. Gagnadoux F, Le Pape A, Urban T, et al. Safety of pulmonary administration of gemcitabine in rats. J. Aerosol Med. 18(2), 198-206 (2005). (Pubitemid 40911360)
44. Lemarie E, Vecellio L, Hureaux J, et al. Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J. Aerosol Med. Pulm. Drug Deliv. 24(6), 261-270 (2011).
45. Min R, Li T, Du J, Zhang Y, Guo J, Lu WL. Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals. Can. J. Physiol. Pharmacol. 86(5), 288-298 (2008). (Pubitemid 351705490)
46. Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. α-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp. Biol. Med. (Maywood). 229(11), 1169-1176 (2004). (Pubitemid 39602260)
47. Azarmi S, Tao X, Chen H, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int. J. Pharm. 319(1-2), 155-161 (2006). (Pubitemid 44051806)
48. El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm. Res. 26(7), 1752-1763 (2009).
49. Chen ST, Karnezis T, Davidson TM. Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia- associated epistaxis. Laryngoscope 121(3), 644-646 (2011).
50. Porpodis K, Konoglou M, Zarogoulidis P, et al. Pulmonary thromboendarterectomy after treatment with treprostenil in a chronic thromboembolic pulmonary hypertension patient: a case report. Int. J. Gen. Med. 4, 767-772 (2011).
51. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56(6), 600-612 (2003). (Pubitemid 37491711)
52. Bosquillon C. Drug transporters in the lung - do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99(5), 2240-2255 (2010).
53. Leclerc J, Courcot-Ngoubo Ngangue E, Cauffiez C, et al. Xenobiotic metabolism and disposition in human lung: transcript profiling in non-tumoral and tumoral tissues. Biochimie 93(6), 1012-1027 (2011).
54. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 71(4), 301-326 (2004). (Pubitemid 39179164)
55. Camus P. Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br. J. Cancer 91(Suppl. 2), S1-S2 (2004). (Pubitemid 39331426)
56. Zhang WB, Gan WE, Lin XQ. Development of a new electrochemical hydride generator with tungsten wire cathode for the determination of As and Sb by atomic fluorescence spectrometry. Talanta 68(4), 1316-1321 (2006).
57. Lam CW, James JT, Mccluskey R, Arepalli S, Hunter RL. A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit. Rev. Toxicol. 36(3), 189-217 (2006).
58. Donaldson K, Murphy FA, Duffin R, Poland CA. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part. Fibre Toxicol. 7, 5 (2010).
59. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small 4(1), 26-49 (2008).
60. Ibrahim BM, Park S, Han B, Yeo Y. A strategy to deliver genes to cystic fibrosis lungs: a battle with environment. J. Control. Release 155(2), 289-295 (2011).
61. Zarogouldis P, Karamanos NK, Porpodis K, et al. Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology. Int. J. Mol. Sci. 13(9), 10828-10862 (2012).
62. Nygren O. Wipe sampling as a tool for monitoring aerosol deposition in workplaces. J. Environ. Monit. 8(1), 49-52 (2006). (Pubitemid 43362484)
63. Lin WY, Kao CH, Wang SJ, Yeh SH. Lung toxicity of chemotherapeutic agents detected by TC-99m DTPA radioaerosol inhalation lung scintigraphy. Neoplasma 42(3), 133-135 (1995).
64. Clark AR. Understanding penetration index measurements and regional lung targeting. J. Aerosol Med. Pulm. Drug Deliv. 25(4), 179-187 (2012).
65. Ari A, Restrepo RD. Aerosol delivery device selection for spontaneously breathing patients: 2012. Respir. Care 57(4), 613-626 (2012).
66. Al-Hallak MH, Sarfraz MK, Azarmi S, Roa WH, Finlay WH, Lobenberg R. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Ther. Deliv. 2(10), 1313-1324 (2011).
67. Lowenthal D, Kattan M. Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatr. Pulmonol. 14(3), 192-196 (1992).
68. Davis JN, Stagg D. Interrelationships of the volume and time components of individual breaths in resting man. J. Physiol. 245(2), 481-498 (1975).
69. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56(6), 588-599 (2003). (Pubitemid 37491710)
70. El-Chemaly S, Levine SJ, Moss J. Lymphatics in lung disease. Ann. NY Acad. Sci. 1131, 195-202 (2008). (Pubitemid 351758514)
71. Cryan SA. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7(1), E20-E41 (2005).
72. Fink K, Boratynski J. The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis. Postepy Hig. Med. Dosw (Online) 66, 609-628 (2012).
73. Bae YH. Interview with Dr You Han Bae: ligand-mediated versus 'passive' targeting approaches in nanoparticle oncology research. Ther. Deliv. 3(8), 933-936 (2012).
74. Klonne DR, Dodd DE, Losco PE, Troup CM, Tyler TR. Two-week aerosol inhalation study on polyethylene glycol (PEG) 3350 in F-344 rats. Drug Chem. Toxicol. 12(1), 39-48 (1989). (Pubitemid 19093793)
75. Gerasimovskaya E, Kratzer A, Sidiakova A, Salys J, Zamora M, Taraseviciene-Stewart L. Interplay of macrophages and T cells in the lung vasculature. Am. J. Physiol. Lung Cell. Mol. Physiol. 302(10), L1014-L1022 (2012).
76. Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: noncytotoxic drugs. Am. Rev. Respir. Dis. 133(3), 488-505 (1986). (Pubitemid 16126287)
77. Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am. Rev. Respir. Dis. 133(2), 321-340 (1986). (Pubitemid 16123932)
78. Rosenow EC 3rd, Myers JL, Swensen SJ, Pisani RJ. Drug-induced pulmonary disease. An update. Chest 102(1), 239-250 (1992).
79. Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open. Respir. Med. J. 6, 63-74 (2012).
80. Miyata D, Fukushima T, Matsunaga M, et al. Fatal pulmonary veno-occlusive disease after chemotherapy for Burkitt's lymphoma. Pediatr. Int. 53(3), 403-405 (2011).
81. Kruger B, Benck U, Singer T, Kramer BK. Drug-induced impairment of renal function. Dtsch Med. Wochenschr 137(38), 1873-1877 (2012).
82. Maestrelli P, Schlunssen V, Mason P, Sigsgaard T. Contribution of host factors and workplace exposure to the outcome of occupational asthma. Eur. Respir. Rev. 21(124), 88-96 (2012).
83. Aldrich TK, Prezant DJ. Adverse effects of drugs on the respiratory muscles. Clin. Chest Med. 11(1), 177-189 (1990). (Pubitemid 20086849)
84. Faiyazuddin M, Mujahid M, Hussain T, et al. Aerodynamics and deposition effects of inhaled submicron drug aerosol in airway diseases. Recent Pat. Inflamm. Allergy Drug Discov. 7(1), 49-61 (2013).
85. Koshkina NV, Golunski E, Roberts LE, Gilbert BE, Knight V. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J. Aerosol Med. 17(1), 7-14 (2004). (Pubitemid 38520668)
86. Zappa F, Droege C, Betticher D, et al. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter Phase II trial (SAKK 19/05). Lung Cancer 78(3), 239-244 (2012).
87. Karnezis TT, Davidson TM. Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121(3), 636-638 (2010).
88. Guldmann R, Dupret A, Nivoix Y, Schultz P, Debry C. Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease. Laryngoscope 122(5), 953-955 (2012).
89. Sadzuka Y, Nagamine M, Toyooka T, Ibuki Y, Sonobe T. Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. Int. J. Pharm. 432(1-2), 42-49 (2012).
90. Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 119(2), 348- 355 (2012).
91. Riedel SB, Fischer SM, Sanders BG, Kline K. Vitamin E analog, a-tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice. Anticancer Drugs 19(2), 175-181 (2008).
92. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol. Sci. 95(2), 300-312 (2007). (Pubitemid 46152602)
93. Pope CA 3rd, Burnett RT, Thun MJ, et al. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 287(9), 1132-1141 (2002). (Pubitemid 34252082)
94. Ahmad S, Raemy DO, Loader JE, et al. Interaction and localization of synthetic nanoparticles in healthy and cystic fibrosis airway epithelial cells: effect of ozone exposure. J. Aerosol Med. Pulm. Drug Deliv. 25(1), 7-15 (2012).
95. Hasleton PS. The internal surface area of the adult human lung. J. Anat. 112(Pt 3), 391-400 (1972).
96. Riedl MA, Nel AE. Importance of oxidative stress in the pathogenesis and treatment of asthma. Curr. Opin. Allergy Clin. Immunol. 8(1), 49-56 (2008).
97. Balstad TR, Carlsen H, Myhrstad MC, et al. Coffee, broccoli and spices are strong inducers of electrophile response element-dependent transcription in vitro and in vivo - studies in electrophile response element transgenic mice. Mol. Nutr. Food Res. 55(2), 185-197 (2011).
98. Peters A, Wichmann HE, Tuch T, Heinrich J, Heyder J. Respiratory effects are associated with the number of ultrafine particles. Am. J. Respir. Crit. Care Med. 155(4), 1376-1383 (1997). (Pubitemid 27172786)
99. Nowak D, Jorres R, Berger J, Claussen M, Magnussen H. Airway responsiveness to sulfur dioxide in an adult population sample. Am. J. Respir. Crit. Care Med. 156(4 Pt 1), 1151-1156 (1997).
100. Mccloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial study group. Ann. Intern. Med. 121(1), 1-5 (1994).
101. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271(23), 1836-1843 (1994). (Pubitemid 24169697)
102. Abraham E, Glauser MP, Butler T, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277(19), 1531-1538 (1997). (Pubitemid 27213302)
103. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N. Engl. J. Med. 317(25), 1565-1570 (1987). (Pubitemid 18014383)
104. Abraham E, Park YC, Covington P, Conrad SA, Schwartz M. Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit. Care Med. 24(1), 10-15 (1996).
105. Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen NO. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit. Care Med. 20(7), 918-923 (1992).
106. Haupt MT, Jastremski MS, Clemmer TP, Metz CA, Goris GB. Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit. Care Med. 19(11), 1339-1347 (1991).
107. Cole SR, Myers TJ, Klatsky AU. Pulmonary disease with chlorambucil therapy. Cancer 41(2), 455-459 (1978). (Pubitemid 8289259)
108. Meignan M, Rosso J, Robert R. Lung epithelial permeability to aerosolized solutes: relation to position. J. Appl. Physiol. 62(3), 902-911 (1987). (Pubitemid 17073881)
109. Rosso J, Guillon JM, Parrot A, et al. Technetium-99m-DTPA aerosol and gallium-67 scanning in pulmonary complications of human immunodeficiency virus infection. J. Nucl. Med. 33(1), 81-87 (1992).
110. Delvadia RR, Longest PW, Byron PR. In vitro tests for aerosol deposition. I: scaling a physical model of the upper airways to predict drug deposition variation in normal humans. J. Aerosol Med. Pulm. Drug Deliv. 25(1), 32-40 (2012).
111. Mitchell J, Copley M, Sizer Y, Russell T, Solomon D. Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" idealized throat (AIT) inlet. J. Aerosol Med. Pulm. Drug Deliv. 25(4), 188-197 (2012).
112. Seger AC, Churchill WW, Keohane CA, et al. Impact of robotic antineoplastic preparation on safety, workflow, and costs. J. Oncol. Prac. 8, 344-350 (2012).
113. Ter Heine R, Van Den Bosch RT, Schaefer-Prokop CM, et al. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung Cancer 75(3), 391-397 (2012).
114. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target. Oncol. 6(4), 235-243 (2011).
115. Joshi N, Kaviratna A, Banerjee R. Multi trigger responsive, surface active lipid nanovesicle aerosols for improved efficacy of paclitaxel in lung cancer. Integr. Biol. (Camb.) 5(1), 239-248 (2013).
116. Tian Y, Klegerman ME, Hickey AJ. Evaluation of microparticles containing doxorubicin suitable for aerosol delivery to the lungs. PDA J. Pharm. Sci. Technol. 58(5), 266-275 (2004). (Pubitemid 40704401)
117. Zou Y, Fu H, Ghosh S, Farquhar D, Klostergaard J. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 10(21), 7382-7391 (2004). (Pubitemid 39487728)